A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.
    Gupta, Vikas
    Baer, Maria R.
    Oh, Stephen T.
    Miller, Carole Brennan
    Jun, Susie
    Lee, Peter
    Dong, Hua
    Reiter, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
    Duan, Minghui
    Ma, Lan
    Wu, Qiuling
    Liang, Hong
    Wang, Wei
    Wu, Shaoling
    Mu, Lijun
    Lin, Hai
    Zhou, Hebing
    Shi, Hong-Xia
    Wang, Jinghua
    Jing, Hongmei
    BLOOD, 2023, 142
  • [33] Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
    Cohen, Fredric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 87 - 94
  • [34] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
    Kropff, Martin
    Kienast, Joachim
    Bisping, Guido
    Berdel, Wolfgang E.
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    Stefanic, Martin
    Munzert, Gerd
    ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
  • [35] CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study.
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noa
    Silverman, Michael H.
    Bar Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Petoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
    Finkel, Richard S.
    Chiriboga, Claudia A.
    Vajsar, Jiri
    Day, John W.
    Montes, Jacqueline
    De Vivo, Darryl C.
    Yamashita, Mason
    Rigo, Frank
    Hung, Gene
    Schneider, Eugene
    Norris, Daniel A.
    Xia, Shuting
    Bennett, C. Frank
    Bishop, Kathie M.
    LANCET, 2016, 388 (10063): : 3017 - 3026
  • [37] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
    Altman, Robert D.
    Lang, Anthony E.
    Postuma, Ronald B.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
  • [38] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.
    Anolik, JH
    Campbell, D
    Ritchlin, C
    Holyst, M
    Rosenfeld, S
    Sanz, I
    Young, F
    Felgar, R
    Kunkel, L
    Benyunes, M
    Grillo-Lopéz, A
    Rosenblatt, J
    Looney, RJ
    ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860
  • [39] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
    Oritani, Kenji
    Okamoto, Shinichiro
    Tauchi, Tetsuzo
    Saito, Shigeki
    Ohishi, Kohshi
    Handa, Hiroshi
    Takenaka, Katsuto
    Gopalakrishna, Prashanth
    Amagasaki, Taro
    Ito, Kazuo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 295 - 304
  • [40] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
    Kenji Oritani
    Shinichiro Okamoto
    Tetsuzo Tauchi
    Shigeki Saito
    Kohshi Ohishi
    Hiroshi Handa
    Katsuto Takenaka
    Prashanth Gopalakrishna
    Taro Amagasaki
    Kazuo Ito
    Koichi Akashi
    International Journal of Hematology, 2015, 101 : 295 - 304
12345